Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 4
More JCP Articles
Original Research
Five-Year Outcomes of First Suicide Attempts: Lethality, Recurrence, and Mortality
September 1, 2025
Recurrence of suicide attempt occurred in 37.2% of patients, with 27.8% having ≥3 attempts. Alcohol use predicted high-lethality first attempts, and female sex predicted multiple reattempts.
Original Research
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
August 27, 2025
This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
Original Research
N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
August 27, 2025
Among individuals with PTSD and alcohol use disorder receiving CBT and either NAC or placebo, both groups had significant reductions in both PTSD symptom severity and alcohol use, with…
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to…
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing…
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
